Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-INHBE in Adults With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
NCT07859813Phase 2Not yet recruiting
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- Oct 2029
01
Overview
Phase 2, randomised, double-blind trial of ARO-INHBE in metabolic dysfunction-associated steatohepatitis (MASH) (6 arms), sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Percent Change From Baseline in Liver Fat Content by Magnetic Resonance Imaging-proton Density Fat Fraction at 48 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ARO-INHBE
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07859813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07859813.